Partner Headlines - BMY

  1. Meet 5 Top Biotech Stocks Holding Up In Shaky Market

    IBD
  2. Celgene drug could gain share

    IBD
  3. Celgene's Abraxane Succeeds In Early Breast Cancer

    IBD
  4. Merck's Keytruda Might Treat Virulent Breast Cancer

    IBD
  5. US Stock Futures Edge Lower Ahead Of Federal Budget

    Benzinga
  6. T Rowe Price's Top Stakes for the Third Quarter

    GuruFocus
  7. I think Zimmer Will Outperform S&P 500 Performance

    GuruFocus
  8. Avanir Stock Jumps On $3.5 Billion Otsuka Buyout

    IBD
  9. A Buy Recommendation From Absolute Valuation Model to Bristol-Myers ...

    GuruFocus
  10. Screening Pharma Stocks Amid Turnaround

    YCharts
  11. Incyte Building Blockbuster Drug One Disease At A Time

    IBD
  12. Blackhill Bets Almost Half of Portfolio on Williams-Sonoma

    GuruFocus
  13. Merck Down On Hepatitis C Data; Gilead Rises

    IBD
  14. A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio

    GuruFocus
  15. Dan Nathan Sees Unusual Options Activity In Bristol-Myers Squibb ...

    Benzinga
  16. Lung cancer drug promising

    IBD
  17. Bristol-Myers Lung-Cancer Drug Boosts Survival

    IBD
  18. #PreMarket Primer: Monday, October 27: ECB Stress Tests In-Line ...

    Benzinga
  19. Eliquis revives Bristol-Myers

    IBD
  20. Bristol-Myers Beats Q3 Views As Eliquis Revives

    IBD
  21. Stocks Flat In Mixed Volume; Amazon.com Weighs On Techs

    IBD
  22. UPDATE: Bristol-Myers Squibb Q3 Earnings Top Estimates

    Benzinga
  23. Stock Futures Aim For Flat Open; Amazon.com Crumples On Q3 Miss

    IBD
  24. #PreMarket Primer: Friday, October 24: Ebola Fears Weigh On Markets

    Benzinga
  25. Earnings Scheduled For October 24, 2014

    Benzinga
  26. Must Watch Stocks for Today

    Benzinga
  27. Stocks Rebound; Amazon.com Slides After Hours

    IBD
  28. Drug ETFs Attractive Buys On Pullback

    Benzinga
  29. Weekly CFO Sells Highlight: Williams Companies Inc, Google Inc, ...

    GuruFocus
  30. Benzinga Weekly Preview: Earnings Season Is In Full Swing

    Benzinga
  31. Apple Leads the Charge as Earnings Season Heats Up

    FoxBusiness
  32. The Six Types of Winning Stocks

    GuruFocus
  33. Markets Debut Week On Negative Note; S&P 500 Falls Through Key ...

    Benzinga
  34. Merck to release hep C data

    IBD
  35. Merck, Bristol, Arrowhead Prep Hepatitis Studies

    IBD
  36. Salix, Actavis Among Big Cap Pharmas In Merger Mambo

    IBD
  37. Bristol-Myers pulls FDA filing

    IBD
  38. Bristol-Myers Pulls FDA Filing For 2-Drug Hep C Combo

    IBD
  39. Bristol-Myers Squibb Statement About Asunaprevir In The US, WIthdraws ...

    Benzinga
  40. 2 Mutual Funds Holding Hospital Stocks

    Benzinga
  41. NeurOp Receives Milestone Payment As Bristol-Myers Squibb Nominates ...

    Benzinga
  42. Morgan Stanley Believes Bristol-Myers Squibb Co. Could Move Significantly ...

    Benzinga
  43. Gilead's New HIV Drug Key To Long-Term Strategy

    IBD
  44. Gilead OKs Generic Sovaldi To Expand Global Access

    IBD
  45. Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. ...

    Benzinga
  46. Merck PD-1 Inhibitor Approved For Skin Cancer

    IBD
  47. Drug M&A Boom Driven By Long-Term Trends: PwC

    IBD
  48. Booming Biotech Market Benefits REIT BioMed Realty

    IBD
  49. Bristol-Myers: Absolute Valuation Model versus Relative Valuation ...

    GuruFocus
  50. Bristol-Myers Drug Gets OK

    IBD
  51. Markets Little Changed In Low Volume And Slow News Ahead Of Long ...

    Benzinga
  52. Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers ...

    Benzinga
  53. Bristol-Myers Hepatitis C Therapy Approved in EU

    IBD
  54. US Stock Futures Edge Higher Ahead Of Tiffany Earnings

    Benzinga
  55. Merck, Pfizer Combining Drugs In Lung Cancer Study

    IBD
  56. Intercept Pharma Soars On Liver-Disease Drug Data

    IBD
  57. Markets Marginally Higher On Light Volume And Encouraging Geopolitical ...

    Benzinga
  58. Drugmaker AstraZeneca Returns To Growth

    IBD
  59. The Stocks Already in Correction Mode

    FoxBusiness
  60. Will ImmunoGen's Q4 Earnings Disappoint Again?

    GuruFocus
  61. Bristol-Myers surprises Street

    IBD
  62. Thursday Morning Earnings Reports

    Benzinga
  63. Stock Futures Steer Higher; Facebook, Skechers Nail Q2 Wins

    IBD
  64. Earnings Scheduled For July 24, 2014

    Benzinga
  65. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  66. Benzinga Weekly Preview: Earnings Season Continues With Geopolitical ...

    Benzinga
  67. UnitedHealth Group Up on Weak Day for the Dow

    GuruFocus
  68. Dow Sets New Intraday High; Citigroup Impresses With Earnings

    Benzinga
  69. Senators Ask Gilead To Explain Sovaldi Pricing

    IBD
  70. Bristol seeks cancer drug nod

    IBD
  71. Bristol-Myers Seeking Nivolumab Approval In Melanoma

    IBD
  72. Japan approves BMY regimen

    IBD
  73. Jazz, Novo Among Medicals Showing Healthy Action

    IBD
  74. Bristol-Myers' All-Oral HCV Therapy Approved In Japan

    IBD
  75. Merck, Gilead Lead Race To Eradicate Hepatitis C

    IBD
  76. Markets Little Changed Ahead Of 4th Of July Break

    Benzinga
  77. Barclays Downgrades Pharmaceutical Sector

    Benzinga
  78. UPDATE: Barclays Downgrades Bristol-Myers, Cuts Price Target ...

    Benzinga
  79. Benzinga's Top Downgrades

    Benzinga
  80. Ex-Dividends For July 1, 2014

    Benzinga
  81. Pfizer and others get EU nods

    IBD
  82. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
  83. Pfizer, Bristol-Myers Squibb Announce Positive Opinion For Treatments

    Benzinga
  84. US Stock Futures Drop Ahead Of Consumer Sentiment Report

    Benzinga
  85. Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza ...

    Benzinga
  86. Pharma Sector Stocks To Consider For Sustained Returns

    GuruFocus
  87. Bristol-Myers Stock Up On Nivolumab Trial Success

    IBD
  88. BRISTOL-MYERS SQUIBB

    IBD
  89. UPDATE: Bristol Myers Announces Phase 3 First-Line Study of Nivolumab ...

    Benzinga
  90. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga
  91. Merck Takes The 'Nuc' Option In Hepatitis C Race

    IBD
  92. ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy

    Benzinga
  93. ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?

    Benzinga
  94. Bristol-Myers Offers Two-, Three-Year Survival Data for Nivolumab

    Benzinga
  95. AstraZeneca Woos Shareholders With Promise Of Growth

    IBD
  96. Vanguard Health Care Fund's Top Quarterly Holdings

    GuruFocus
  97. Bristol, Merck Q1 sales soft

    IBD
  98. Bristol, Merck, Sanofi Report Soft Q1 Sales

    IBD
  99. ETF Outlook For Tuesday, April 29, 2014 (IHE, TAN, XRT, SOCL, ...

    Benzinga
  100. UPDATE: Bristol-Myers Posts Higher Q1 Profit

    Benzinga
Trading Center